Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
March 29 2017 - 4:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced
that it will present at the 16th Annual Needham Healthcare
Conference in New York, NY on Wednesday, April 5 at 12:10 p.m.
Eastern Time.
The presentation will be webcast live and available for replay
from GBT’s website at www.globalbloodtx.com in the Investors
section.
About Global Blood
TherapeuticsGlobal Blood Therapeutics, Inc. is a
clinical-stage biopharmaceutical company dedicated to discovering,
developing and commercializing novel therapeutics to treat grievous
blood-based disorders with significant unmet need. GBT is
developing its lead product candidate, GBT440, as an oral,
once-daily therapy for sickle cell disease. GBT is also
investigating GBT440 for the treatment of hypoxemic pulmonary
disorders in two ongoing Phase 2a studies in patients with
idiopathic pulmonary fibrosis. To learn more, please visit:
www.globalbloodtx.com and follow the company on Twitter:
@GBT_News.
Forward-Looking Statements
Statements we make in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. We intend these forward-looking statements, including
statements regarding the therapeutic potential and safety profile
of GBT440, and our ability to implement our clinical development
plans for GBT440, to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Securities Exchange Act and
are making this statement for purposes of complying with those safe
harbor provisions. These forward-looking statements reflect our
current views about our plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to us and on assumptions we have made. We can give no
assurance that the plans, intentions, expectations or strategies
will be attained or achieved, and furthermore, actual results may
differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors
that are beyond our control including, without limitation, the
risks that our clinical and preclinical development activities may
be delayed or terminated for a variety of reasons, that regulatory
authorities may disagree with our clinical development plans or
require additional studies or data to support further clinical
investigation of our product candidates, and that drug-related
adverse events may be observed in later stages of clinical
development, along with those risks set forth in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2016, and in
our Quarterly Reports on Form 10-Q for the quarters ended March 31,
2016, June 30, 2016 and September 30, 2016, as well as discussions
of potential risks, uncertainties and other important factors in
our subsequent filings with the U.S. Securities and Exchange
Commission. Except as required by law, we assume no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
investor@globalbloodtx.com
Julie Normart (media)
Pure Communications
415-946-1087
media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024